BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36949709)

  • 1. [Risk Factors of Rapidly Progressive Interstitial Lung Disease in Patients With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis].
    Han YY; Jiang T; Zhang ZH; Li W; Jiang YD; Lu CC; Fei Y; Chen B
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):422-425. PubMed ID: 36949709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
    Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
    J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases.
    Cheng L; Xu L; Xu Y; Yuan F; Li J; Wu M; Da Z; Wei H; Zhou L; Yin S; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Liu H; Ren T; Zang Y
    Clin Rheumatol; 2024 Jan; 43(1):339-347. PubMed ID: 37985533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
    Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum IgA levels for predicting the development of rapidly progressive interstitial lung disease in dermatomyositis.
    Zhang H; Liang R; Yuan X; Zheng Z; Lai W
    Respir Med; 2023 Sep; 216():107322. PubMed ID: 37302423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease.
    Guo L; Zhang X; Pu W; Zhao J; Wang K; Zhang D; Hong S; Ma Y; Wang X; Ye S; Guo Q; Wang J
    Rheumatology (Oxford); 2023 Jun; 62(6):2320-2324. PubMed ID: 36637178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China.
    You H; Wang L; Wang J; Lv C; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
    Rheumatology (Oxford); 2023 Mar; 62(3):1216-1226. PubMed ID: 35961045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
    Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
    Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Three Different Phenotypes in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung Disease.
    Xu L; You H; Wang L; Lv C; Yuan F; Li J; Wu M; Da Z; Wei H; Yan W; Zhou L; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Du Y; Xue J; Zhang M; Tan W
    Arthritis Rheumatol; 2023 Apr; 75(4):609-619. PubMed ID: 35849805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.
    Hata K; Kotani T; Matsuda S; Fujiki Y; Suzuka T; Kiboshi T; Wada Y; Shiba H; Shoda T; Kagitani M; Takeuchi T
    Int J Rheum Dis; 2024 Jan; 27(1):e14999. PubMed ID: 38063858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
    Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
    Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypouricemia as a novel predictor of mortality in anti-MDA5 positive dermatomyositis patients with ILD: A retrospective cohort study.
    Liu H; Chen B; Guo Y; Liu H; Ran J; Liu R; Yin G; Xie Q
    Respir Med; 2024 Feb; 222():107530. PubMed ID: 38228214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients.
    Hensgens MPM; Delemarre EM; Drylewicz J; Voortman M; Krol RM; Dalm VASH; Miedema JR; Wiertz I; Grutters J; Limper M; Nierkens S; Leavis HL
    Rheumatology (Oxford); 2022 Oct; 61(10):4087-4096. PubMed ID: 35048953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
    Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
    Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDA5 expression is associated with TGF-β-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis.
    Shen N; Zhou X; Jin X; Lu C; Hu X; Zhang Y; Jiang Y; Xu Q; Xu X; Liu M; Lu L; Han Y
    Rheumatology (Oxford); 2022 Dec; 62(1):373-383. PubMed ID: 35412608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
    Horino T; Inotani S; Nakajima K; Ohnishi H; Komori M; Terada Y
    Joint Bone Spine; 2022 Nov; 89(6):105456. PubMed ID: 36108903
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients.
    Yang Q; Li T; Zhang X; Lyu K; Wu S; Chen Y; Liu S; Yu Z
    Orphanet J Rare Dis; 2021 Jan; 16(1):58. PubMed ID: 33516242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease].
    Zou RY; Zhao Q; Tian YQ; Yan X; Qiu XH; Gao YJ; Liu Y; Huang M; Cao M; Dai JH; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):781-790. PubMed ID: 37536988
    [No Abstract]   [Full Text] [Related]  

  • 20. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis.
    Shimizu T; Koga T; Furukawa K; Horai Y; Fujikawa K; Okada A; Okamoto M; Endo Y; Tsuji S; Takatani A; Umeda M; Fukui S; Sumiyoshi R; Kawashiri SY; Iwamoto N; Igawa T; Ichinose K; Tamai M; Sakamoto N; Nakamura H; Origuchi T; Mukae H; Kuwana M; Kawakami A
    J Intern Med; 2021 Feb; 289(2):206-220. PubMed ID: 32691471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.